Valion Bio, Inc. closed a $7,737,000 purchase of Series B and C Preferred Shares and warrants from investor 3i, LP on August 31, 2026. The transaction involved the issuance of 100 Series B shares with warrants for 3,077 common shares at a $3.62 exercise price, plus 7,637 Series C shares with warrants for 1,053,969 common shares at the same price. Payment consisted of $1.5 million in cash, with the remainder offset against overdue true-up payments and legal fees. The closing occurred after a 1-for-25 reverse stock split effective August 31, 2026. Concurrently, the Board appointed Jared Malbin and Thomas Jensen as directors to strengthen capital markets and biotechnology expertise. Executive leadership shifted as CFO Lisa Wolf assumed the roles of President and COO following CEO Michael Handley's departure. Valion Bio is a clinical-stage biopharmaceutical company developing Entolimod for Acute Radiation Syndrome.

Valion Bio, Inc. issued 250 Series B Preferred Shares at $1,000 per share and a warrant to purchase 156,026 shares of common stock at an exercise price of $0.616280 per share to 3i, LP for an aggregate purchase price of $250,000 on June 17, 2026. The company is a biotechnology company focused on developing medical devices or health technology solutions.